Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup Arbor

Chiesi Global Rare Diseases is committing up to $115 million to begin a collaboration on Arbor Biotechnologies’ in vivo gene-editing therapy for primary hyperoxaluria type 1, an inherited liver disorder. It’s the rare disease company’s first foray into genetic medicines. The post Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup…

Read More

Senators Press Deloitte, Other Contractors on Errors in Medicaid Eligibility Systems

Senators have launched an inquiry into companies paid billions in taxpayer dollars to build eligibility systems for Medicaid, expressing concern that error-riddled technology and looming work requirements “will cause Americans to lose Medicaid coverage to this bureaucratic maze.” The letters, dated Oct. 10, were sent to four companies and follow a KFF Health News investigation…

Read More

Designating English as the Official Language of the United States Could Impact Millions with Limited English Proficiency

This issue brief provides an overview of Executive Order (EO) 14224 designating English as the official language of the United States and its potential implications for multilingual resources, including data on the shares of individuals with LEP across different socioeconomic characteristics based on KFF analysis of 2023 American Community Survey (ACS) data.

Read More